Juniper Pharmaceuticals (JNP) 10-Q 31 Oct 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 27, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'CBRX	'
Entity Registrant Name	'COLUMBIA LABORATORIES INC	'
Entity Central Index Key	'0000821995	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	10,771,851

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$16,397	$20,715
Accounts receivable, net	5,252	7,197
Amounts due from related parties	'	900
Inventories	2,857	2,584
Prepaid expenses and other current assets	1,328	831
Total current assets	25,834	32,227
Property and equipment, net	13,482	13,226
Intangible assets, net	2,418	2,828
Goodwill	10,982	11,152
Deferred tax assets	917	570
Other assets	89	89
Total assets	53,722	60,092
Current liabilities:	'	'
Accounts payable	1,134	2,805
Accrued expenses	2,891	2,488
Deferred revenue	904	754
Notes payable	252	250
Total current liabilities	5,181	6,297
Deferred revenue, net of current portion	1,818	2,243
Notes payable, net of current portion	3,503	3,745
Common stock warrant liability	0	379
Total liabilities	10,502	12,664
Commitments and contingencies	'	'
Contingently redeemable series C preferred stock, 0.55 shares issued and outstanding (liquidation preference of $550)	550	550
Shareholders' equity:	'	'
Preferred stock, $0.01 par value; 1,000 shares authorized Series B convertible preferred stock, 0.13 shares issued and outstanding (liquidation preference of $13)	0	0
Common stock $0.01 par value; 150,000 shares authorized; 12,183 issued and 10,772 outstanding at September 30, 2014 and 12,152 shares issued and outstanding at December 31, 2013	122	122
Additional paid-in capital	287,501	287,048
Treasury stock (at cost), 1,411 shares at September 30, 2014	-8,579	'
Accumulated deficit	-237,370	-241,662
Accumulated other comprehensive income	996	1,370
Total shareholders' equity	42,670	46,878
Total liabilities and shareholders' equity	$53,722	$60,092

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	12,183,000	12,152,000
Common stock, shares outstanding	10,772,000	12,152,000
Purchase of treasury shares	1,411,000	'
Redeemable Series C Preferred Stock [Member]	'	'
Preferred stock, shares issued	550	550
Preferred stock, shares outstanding	550	550
Preferred stock, liquidation preference, value	$550	$550
Series B Convertible Preferred Stock [Member]	'	'
Preferred stock, shares issued	130	130
Preferred stock, shares outstanding	130	130
Preferred stock, liquidation preference, value	$13	$13

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues	'	'	'	'
Product revenues	$5,905	$5,456	$12,707	$17,848
Product revenues from related party	'	'	167	'
Service revenues	2,304	644	7,327	644
Royalties	3,254	107	4,653	284
Royalties from related party	'	888	714	2,524
Other revenues	'	31	'	119
Total net revenues	11,463	7,126	25,568	21,419
Cost of product revenues	3,383	2,748	7,762	8,420
Cost of service revenues	1,717	491	5,479	491
Total cost of revenues	5,100	3,239	13,241	8,911
Gross profit	6,363	3,887	12,327	12,508
Operating expenses	'	'	'	'
Sales and marketing	467	79	1,335	79
Acquisition-related expenses	'	947	'	1,440
Research and development	236	'	312	'
General and administrative	2,148	1,594	6,762	5,881
Total operating expenses	2,851	2,620	8,409	7,400
Income from operations	3,512	1,267	3,918	5,108
Interest (expense) income, net	-29	1	-92	96
Change in fair value of common stock warrant liability	1	428	380	478
Other income (expense), net	76	25	154	-57
Total non-operating income	48	454	442	517
Income before income taxes	3,560	1,721	4,360	5,625
(Benefit from) provision for income taxes	-110	3	68	8
Net income	$3,670	$1,718	$4,292	$5,617
Basic net income per common share	$0.34	$0.15	$0.38	$0.51
Diluted net income per common share	$0.34	$0.11	$0.34	$0.46
Basic weighted average common shares outstanding	10,749	11,138	11,339	10,994
Diluted weighted average common shares outstanding	10,758	11,293	11,355	11,148

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net income	$3,670	$1,718	$4,292	$5,617
Other comprehensive income (loss) components:	'	'	'	'
Foreign currency translation	-1,191	638	-374	635
Unrealized loss on short-term investments	'	'	'	-80
Reclassification adjustment for gains included in net income	'	'	'	-17
Total other comprehensive income (loss)	-1,191	638	-374	538
Comprehensive income	$2,479	$2,356	$3,918	$6,155

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Operating activities:	'	'
Net income	$4,292	$5,617
Reconciliation of net income to net cash provided by operating activities:	'	'
Depreciation and amortization	1,464	376
Change in fair value of common stock warrant liability	-380	-478
Provision for sales returns	'	-26
Stock-based compensation expense	457	338
Deferred income taxes	-354	'
Gain on short-term investments	'	-17
Loss on disposal of fixed assets	'	37
Changes in operating assets and liabilities:	'	'
Accounts receivable	1,888	-2,026
Due from related party	900	1,294
Inventories	-273	635
Prepaid expenses and other current assets	-510	-547
Other non-current assets	'	-86
Accounts payable	-1,672	95
Accrued expenses	364	-137
Deferred revenue	-236	-160
Net cash provided by operating activities	5,940	4,915
Investing activities:	'	'
Purchases of property and equipment	-1,542	-247
Cash paid for acquisition, net of cash received	'	-14,516
Proceeds from the sale of short-term investments	'	15,354
Net cash (used in) provided by investing activities	-1,542	591
Financing activities:	'	'
Proceeds from exercise of common stock options	17	10
Purchase of treasury stock	-8,509	'
Principal payments on notes payable	-184	-7
Dividends paid	-21	-21
Net cash used in financing activities	-8,697	-18
Effect of exchange rate changes on cash and cash equivalents	-19	125
Net (decrease) increase in cash and cash equivalents	-4,318	5,613
Cash and cash equivalents, beginning of period	20,715	13,204
Cash and cash equivalents, end of period	16,397	18,817
Supplemental cash flow information	'	'
Cash paid for interest	93	5
Cash paid for income taxes	3	3
Supplemental noncash financing activities	'	'
Common stock issued in connection with the acquisition of Molecular Profiles	'	$8,106

Interim_Consolidated_Financial

Interim Consolidated Financial Statements	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Interim Consolidated Financial Statements	'
	(1) Interim Consolidated Financial Statements
	The accompanying unaudited interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. It is recommended that these financial statements be read in conjunction with the consolidated financial statements and related notes that appear in the Annual Report on Form 10-K of Columbia Laboratories, Inc. (“Columbia” or the “Company”) for the year ended December 31, 2013 filed with the SEC on March 5, 2014. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the consolidated financial information for the interim periods reported have been made. Results of operations for the nine months ended September 30, 2014 are not necessarily indicative of the results for the year ending December 31, 2014 or any period thereafter.
	Reclassifications
	For comparability purposes, certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period’s presentation within the consolidated statements of operations.
	Management Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to revenue recognition, sales return reserves, allowance for doubtful accounts, inventory reserve, impairment analysis of goodwill and intangibles including their useful lives, deferred tax assets, liabilities and valuation allowances, common stock warrant valuations, and fair value of stock options. On an ongoing basis, management evaluates its estimates. Actual results could differ from those estimates.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	(2) Inventories
	Inventories are stated at the lower of cost (first-in, first-out) or market. Components of inventory cost include materials, labor and manufacturing overhead. Inventories consist of the following (in thousands):
		September 30,		December 31,
		2014		2013
	Raw materials	$	480	$	771
	Work in process		1,677		775
	Finished goods		700		1,038
	Total	$	2,857	$	2,584

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets	'
	(3) Goodwill and Intangible Assets
	Changes to goodwill during the nine months ended September 30, 2014 were as follows (in thousands):
		Total
	Balance—December 31, 2013	$	11,152
	Effects of foreign currency translation		(170	)
	Balance—September 30, 2014	$	10,982
	Intangible assets consist of the following at September 30, 2014 and December 31, 2013 (in thousands):
		Trademark			Developed			Customer			Total
					Technology			Relationships
	Gross carrying amount—September 30, 2014	$	300		$	1,370		$	1,240		$	2,910
	Translation adjustment		9			41			37			87
	Accumulated amortization		(107	)		(282	)		(190	)		(579	)
	Balance—September 30, 2014	$	202		$	1,129		$	1,087		$	2,418
		Trademark			Developed			Customer			Total
					Technology			Relationships
	Gross carrying amount—December 31, 2013	$	300		$	1,370		$	1,240		$	2,910
	Translation adjustment		13			62			56			131
	Accumulated amortization		(36	)		(91	)		(86	)		(213	)
	Balance—December 31, 2013	$	277		$	1,341		$	1,210		$	2,828
	Amortization expense related to the developed technology is classified as a component of cost of service revenues in the accompanying consolidated statements of operations. Amortization expense related to trademark and customer relationships is classified as a component of general and administrative expenses in the accompanying consolidated statements of operations.
	Amortization expense for the three months ended September 30, 2014 was $0.1 million. Amortization expense for the nine months ended September 30, 2014 was $0.4 million. There was no amortization expense for the three and nine months ended September 30, 2013. As of September 30, 2014, amortization expense on existing intangible assets for the next five years and beyond is as follows (in thousands):
	Year ending December 31,	Total
	Remainder of 2014	$	137
	2015		527
	2016		478
	2017		380
	2018		348
	2019 and thereafter		548
	Total	$	2,418

Debt_and_other_Contractual_Obl

Debt and other Contractual Obligations	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt and other Contractual Obligations	'
	(4) Debt and other Contractual Obligations
	In September 2013, Columbia assumed debt of $3.9 million in connection with its acquisition of Molecular Profiles. Molecular Profiles had entered into a Business Loan Agreement (“Loan Agreement”) covering three loan facilities with Lloyds TSB Bank (“Lloyds”), as administrative agent, to fund the construction and expansion of the facility, which includes analytical labs, office space, and a manufacturing facility in the United Kingdom. Prior to the acquisition, Molecular Profiles had drawn down $3.9 million under the loan facilities and as of September 30, 2014 owes $3.8 million under the Loan Agreement. The three loan facilities are each repayable in monthly installments, that began in February 2013 for one of the facilities and in October 2013 for the other two facilities. Repayment of the three facilities is scheduled to occur over a 15 year period from the date of drawdown. Two of the facilities bear interest at the Bank of England’s base rate plus 1.95% and 2.55%, respectively. The interest rate at September 30, 2014 for these two facilities was 2.45% and 3.05%, respectively. The third facility is a fixed rate agreement bearing interest at 3.52% per annum. The weighted average interest rate for the three loan facilities for the three and nine months ended September 30, 2014 was 3.00%. Borrowings under the Loan Agreement are secured by the mortgaged property and an unlimited lien on other assets of Molecular Profiles. The Loan Agreement contains financial covenants that limit the amount of indebtedness the Company may incur, requires the Company to maintain certain levels of net worth, and restricts the Company’s ability to materially alter the character of its business. As of September 30, 2014, the Company is in compliance with all of the covenants under the Loan Agreement.
	Columbia assumed a $2.5 million obligation under a grant arrangement with the Regional Growth Fund on behalf of the Secretary of State for Business, Innovation, and Skills in the United Kingdom. Molecular Profiles used this grant to fund the expansion of its facility. As part of the arrangement, the Company is required to create and maintain certain full-time equivalent personnel levels through October 2017. As of September 30, 2014, the Company is in compliance with the covenants of the arrangement.
	The Regional Growth Fund obligation is recognized in the other income (expense), net line item in the consolidated statement of operations and is recognized on a decelerated basis over the obligation period through October 2017. As of September 30, 2014, the obligation is valued at $2.3 million and is recorded as deferred revenue on the consolidated balance sheets. The amount of other income on the obligation that will be recognized provided the Company remains in compliance with the covenants will be the following (in thousands):
	Year	Total
	Remainder of 2014	$	130
	2015		585
	2016		844
	2017		779
	Total	$	2,338

Geographic_Information_and_Con

Geographic Information and Concentrations	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Geographic Information and Concentrations	'
	(5) Geographic Information and Concentrations
	The Company and its subsidiaries are engaged in one line of business: providing pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, developing new product candidates and the manufacture and supply of CRINONE® (progesterone gel) to its licensee, Merck Serono. The Company has consolidated and runs all of its operational functions from one location in Nottingham, United Kingdom. The Company owns certain plant and equipment physically located at third party contractor facilities in the United Kingdom and Switzerland. The Company’s largest customer, Merck Serono, utilizes a Switzerland-based subsidiary to acquire product from us, which it then sells throughout the world excluding the United States.
	The following tables show selected information by geographic area (in thousands):
	Revenues:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	United States	$	4,428	$	1,026	$	9,074	$	2,928
	Switzerland		6,039		5,456		13,112		17,822
	Other countries		996		644		3,382		669
	Total	$	11,463	$	7,126	$	25,568	$	21,419
	Total assets:
		September 30,		December 31,
		2014		2013
	United States	$	17,251	$	20,278
	Switzerland		757		3,063
	United Kingdom		35,529		36,487
	Other countries		185		264
	Total	$	53,722	$	60,092
	Long-lived assets:
		September 30,		December 31,
		2014		2013
	United States	$	254	$	306
	Switzerland		7		22
	United Kingdom		13,308		12,987
	Other countries		2		—
	Total	$	13,571	$	13,315
	No other individual country represented greater than 10% of total revenues, total assets, or total long-lived assets for any period presented.
	For the three months ended September 30, 2014 and 2013, Merck Serono, Lil’ Drug Store Products, Inc. (“Lil’ Drug Store”) and Actavis, Inc. (“Actavis”) accounted for 52%, 19% and 9%, and 77%, 2% and 12% of net revenues, respectively. For the nine months ended September 30, 2014, Merck Serono, and Actavis accounted for 49% and 13%, respectively, and for the nine months ended September 30, 2013, Merck Serono and Actavis accounted for 83% and 12% of net revenues, respectively. No additional customers accounted for 10% or more of total revenues for the three or nine months ended September 30, 2014 and 2013.

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	(6) Property and Equipment
	Property and equipment consists of the following (in thousands):
		Estimated	September 30, 2014			December 31, 2013
		Useful Life	Cost			Cost
		(Years)
	Machinery and equipment	10-Mar	$	5,212		$	4,288
	Furniture and fixtures	5-Mar		1,019			1,010
	Computer equipment and software	3		186			183
	Buildings and leasehold improvements	Up to 39		9,469			9,616
	Land	Indefinite		617			627
	Construction in-process			642			104
				17,145			15,828
	Less: Accumulated depreciation			(3,663	)		(2,602	)
	Total		$	13,482		$	13,226
	Depreciation expense for the three months ended September 30, 2014 and 2013 was $0.4 million and $0.2 million, respectively. Depreciation expense for the nine months ended September 30, 2014 and 2013 was $1.1 million and $0.4 million, respectively.

Sales_Returns_Reserves

Sales Returns Reserves	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Sales Returns Reserves	'
	(7) Sales Returns Reserves
	Currently there is no sales returns reserve as the return rights obligation has elapsed for all products for which Columbia provided a right of return. Products sold to Merck Serono and Actavis are not returnable to Columbia nor is Columbia responsible for returns to Merck Serono on international product sales. A sales return reserve previously existed for Columbia’s historic return policy which allowed product to be returned for a period beginning three months prior to the product expiration date and ending twelve months after the product expiration date. Columbia was only responsible for sales returns for CRINONE and PROCHIEVE products sold to domestic customers prior to the Actavis transaction in July 2010, and for STRIANT sold prior to the sale of STRIANT® (testosterone buccal system) to Auxilium Pharmaceuticals LLC (“Auxilium”) in April 2011.
	An analysis of the reserve for sales returns at September 30, 2014 is as follows (in thousands):
		Total
	Balance—December 31, 2013	$	138
	Provision:
	Related to current period sales		—
	Related to prior period sales		(136	)
			2
	Returns:
	Related to current period sales		—
	Related to prior period sales		(2	)
			(2	)
	Balance—September 30, 2014	$	—

Net_Income_Per_Common_Share

Net Income Per Common Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Income Per Common Share	'
	(8) Net Income Per Common Share
	The calculation of basic and diluted income per common and common equivalent share is as follows (in thousands except for per share data):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Basic income per common share
	Net income	$	3,670		$	1,718		$	4,292		$	5,617
	Less: Preferred stock dividends		(7	)		(7	)		(21	)		(21	)
	Net income applicable to common stock	$	3,663		$	1,711		$	4,271		$	5,596
	Basic weighted average number of common shares outstanding		10,749			11,138			11,339			10,994
	Basic net income per common share	$	0.34		$	0.15		$	0.38		$	0.51
	Diluted income per common share
	Net income applicable to common stock	$	3,663		$	1,711		$	4,271		$	5,596
	Add: Preferred stock dividends		7			7			21			21
	Less: Fair value of stock warrants for dilutive warrants		(1	)		(428	)		(380	)		(478	)
	Net income applicable to dilutive common stock	$	3,669		$	1,290		$	3,912		$	5,139
	Basic weighted average number of common shares outstanding		10,749			11,138			11,339			10,994
	Effect of dilutive securities
	Dilutive stock awards		—			13			—			12
	Dilutive preferred share conversions		9			142			16			142
			9			155			16			154
	Diluted weighted average number of common shares outstanding		10,758			11,293			11,355			11,148
	Diluted net income per common share	$	0.34		$	0.11		$	0.34		$	0.46
	Basic income per common share is computed by dividing the net income, less preferred dividends by the weighted-average number of shares of common stock outstanding during a period. The diluted earnings per common share calculation gives effect to dilutive options, warrants, convertible notes, convertible preferred stock, and other potential dilutive common stock including selected restricted shares of common stock outstanding during the period. Diluted income per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options, assuming the exercise of all in-the-money stock options. Common share equivalents have been excluded where their inclusion would be anti-dilutive.
	Shares to be issued upon the exercise of the outstanding options and warrants, convertible preferred stock and selected restricted shares of common stock excluded from the income per share calculation amounted to 1.8 million and 1.6 million in each of the three month periods ended September 30, 2014 and 2013, respectively, because the awards were anti-dilutive. Shares to be issued upon the exercise of the outstanding options and warrants, convertible preferred stock and selected restricted shares of common stock excluded from the income per share calculation amounted to 1.8 million and 1.6 million in each of the nine month periods ended September 30, 2014 and 2013, respectively, because the awards were anti-dilutive.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Accumulated Other Comprehensive Income	'
	(9) Accumulated Other Comprehensive Income
	Changes to accumulated other comprehensive income during the nine months ended September 30, 2014 were as follows (in thousands):
		Translation			Accumulated Other
		Adjustment			Comprehensive
					Income
	Balance—December 31, 2013	$	1,370		$	1,370
	Current period other comprehensive income		(374	)		(374	)
	Balance—September 30, 2014	$	996		$	996

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	(10) Stock-Based Compensation
	Columbia recorded stock-based compensation expense of $0.1 million for both three month periods ended September 30, 2014 and 2013. Stock-based compensation expense for the nine months ended September 30, 2014 and 2013 was $0.5 million and $0.3 million, respectively.
	Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individuals holding the respective options as follows (in thousands):
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014			2013		2014		2013
	Cost of revenues	$	15		$	5	$	28	$	10
	Sales and marketing		13			—		29		—
	General and administrative		83			60		400		328
	Total	$	111		$	65	$	457	$	338
	Cash received from option exercises for the nine months ended September 30, 2014 and 2013 was $17,000 and $10,000, respectively.
	Columbia granted 222,000 and 88,750 stock options during the nine months ended September 30, 2014 and 2013, respectively.
	The Company uses the Black-Scholes option pricing model to determine the estimated grant date fair values for stock-based awards. The weighted-average grant date fair values of the options granted during the nine months ended September 30, 2014 and 2013 were $4.51 and $3.52, respectively, using the following assumptions:
		Nine Months Ended
		September 30,
		2014			2013
	Risk free interest rate		1.64	%	0.71%-0.76%
	Expected term		4.75 years		4.75 years
	Dividend yield		—		—
	Expected volatility		81.36	%	96.52%-97.02%
	Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. Columbia’s estimated expected stock price volatility is based on its own historical volatility. Columbia’s expected term of options granted during the nine months ended September 30, 2014 and 2013 was derived using the simplified method. The risk-free rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant.
	As of September 30, 2014, the total unrecognized compensation cost related to outstanding stock options and restricted stock awards expected to vest was $1.1 million, which the Company expects to recognize over a weighted-average period of 2.94 years.

Legal_Proceedings

Legal Proceedings	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Legal Proceedings	'
	(11) Legal Proceedings
	Claims and lawsuits are filed against the Company from time to time. Although the results of pending claims are always uncertain, the Company believes that it has adequate reserves or adequate insurance coverage in respect of these claims, but no assurance can be given as to the sufficiency of such reserves or insurance coverage in the event of any unfavorable outcome resulting from these actions.
	Between February 1, 2012 and February 6, 2012, two putative securities class action complaints were filed against Columbia and certain of its officers and directors in the United States District Court for the District of New Jersey. These actions were filed under the captionsWright v. Columbia Laboratories, Inc., et al., and Shu v. Columbia Laboratories, Inc., et al. and asserted claims under sections 10(b) and 20(a) of the Securities Exchange Act of 1934 as amended (the “Exchange Act”) and Rule 10b-5 promulgated under the Exchange Act on behalf of an alleged class of purchasers of the common stock during the period from December 6, 2010 through January 20, 2012. Both actions were consolidated into a single proceeding entitled In re Columbia Laboratories, Inc., Securities Litigation, under which Actavis and three of its officers have been added as defendants. The Consolidated Amended Complaint alleged that Columbia and two of its officers, one of whom is a director, omitted to state material facts that they were under a duty to disclose, and made materially false and misleading statements that related to the results of Columbia’s PREGNANT study and the likelihood of approval by the U.S. Food and Drug Administration (“FDA”) of a New Drug Application (“NDA”) to market progesterone vaginal gel 8% for the prevention of preterm birth in women with premature cervical shortening. According to the amended complaint, these alleged omissions and misleading statements had the effect of artificially inflating the market price of the common stock. The plaintiffs sought unspecified damages on behalf of the putative class and an award of costs and expenses, including attorney’s fees. On June 11, 2013, the Court dismissed the amended complaint for failure to state a claim upon which relief could be granted, holding that the plaintiffs did not adequately plead facts supporting an inference of an intent to deceive investors. The Court permitted the plaintiffs to file a second amended complaint, which they did on July 11, 2013. Columbia moved to dismiss the second amended complaint, which the court did on October 21, 2013. The Court ruled that changes the plaintiffs made to their first amended complaint “still do not create a strong inference that the Defendants acted with an intent to deceive, manipulate or defraud.” The Court ordered that if the plaintiffs sought to attempt to plead a cognizable action in a third amended complaint, they must do so within thirty days and specifically address why the attempt would not be futile. The plaintiffs chose not to file any further amendments and the case was dismissed with prejudice on December 2, 2013. On December 20, 2013, the plaintiffs appealed the dismissal to the United States Court of Appeals for the Third Circuit. Briefing of the appeal is complete, and the Court has scheduled an oral argument in December 2014. Columbia believes that the appealed action is without merit, and intends to defend it vigorously. At this time, it is not possible to determine the likely outcome of, or to estimate the potential liability related to this action, and Columbia has not made any provision for losses in connection with it.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	(12) Fair Value of Financial Instruments
	U.S. GAAP establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined as the amount that would be received for an asset or paid to transfer a liability (i.e., an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes the following fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value:
	Level 1: Quoted prices in active markets for identical assets and liabilities.
	Level 2: Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The fair value of cash and cash equivalents are classified as Level 1 at September 30, 2014 and December 31, 2013.
	The estimated fair value of the common stock warrant liability resulting from the October 2009 registered direct offering of 1,362,500 shares of common stock and warrants to purchase 681,275 shares of common stock was $0.4 million as of December 31, 2013. There was no value associated with the common stock warrant liability as of September 30, 2014. The value as of December 31, 2013 was determined by using the Black-Scholes option pricing model, which is based on the Company’s stock price at measurement date, exercise price of the common stock warrants, risk-free interest rate and historical volatility, and are classified as a Level 2 measurement. During the three months ended September 30, 2014 and 2013, the Company recorded income of $1,000 and $0.4 million, respectively, to adjust the value of the common stock warrant liability to fair value. During the nine months ended September 30, 2014 and 2013, the Company recorded income of $0.4 million and $0.5 million, respectively, to adjust the value of the common stock warrant liability to fair value.
	The fair values of accounts receivable and accounts payable approximate their respective carrying amounts. The Company’s long-term debt is carried at amortized face value, which approximates fair value based on current market pricing of similar debt instruments and is categorized as a Level 2 measurement.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	(13) Related Party Transactions
	On March 7, 2014 the Company acquired all of its common stock beneficially owned by Actavis, which represented approximately 11.5% of the Company’s outstanding common stock. Immediately following the closing of the stock repurchase and as of September 30, 2014, Actavis did not own any of the Company’s outstanding common stock. Columbia purchased the 1.4 million shares held by Actavis at a price of $6.08 per share, which represented a 10.75% discount to the market closing price on March 6, 2014. The total purchase price was approximately $8.5 million.
	Pursuant to its Purchase and Collaboration Agreement with Actavis, Columbia receives royalties equal to a minimum of 10% of annual net sales of CRINONE by Actavis for annual net sales up to $150 million; 15% for sales above $150 million but less than $250 million; and 20% for annual net sales of $250 million and over. Actavis also purchased for $0.2 million the remaining raw materials Columbia had on hand in the nine months ended September 30, 2014.
	The table below presents the transactions between the Company and Actavis during the three months ended September 30, 2014 and 2013 and the nine months ended September 30, 2014 (prior to the time Actavis ceased to be a related party) and the nine months ended September 30, 2013 (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Revenues
	Product revenues	$	—	$	—	$	167	$	—
	Royalties		—		888		714		2,524
	Total revenues	$	—	$	888	$	881	$	2,524
	As of September 30, 2014 any amounts due from Actavis are now classified as a component of accounts receivable, net on the consolidated balance sheet. At December 31, 2013, amounts due from Actavis for these sales were $0.9 million. There were no amounts due to Actavis at September 30, 2014 and December 31, 2013.

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	(14) Income Taxes
	During the three months ended September 30, 2014 Columbia recorded an income tax benefit of $0.1 million representing an effective tax rate of (3%). During the three months ended September 30, 2013, Columbia recorded income tax expense of $3,000, representing an effective tax rate of 0.2%. During the nine months ended September 30, 2014 and 2013, Columbia recorded income tax expense of $0.1 million and $8,000, respectively, representing an effective tax rate of 2% and 0.1%, respectively. The income tax provision for the three months ended September 30, 2014 is primarily attributable to a benefit recorded due to taxable losses generated in foreign jurisdictions. The income tax provision for the nine months ended September 30, 2014 is primarily attributable to a one-time clawback provision under a New Jersey Economic Development Authority program relating to the sale of the Company’s state net operating losses, offset partially by a benefit recorded due to taxable losses generated in foreign jurisdictions.
	Columbia files income tax returns in the U.S. federal jurisdiction, and in various state and foreign jurisdictions. Columbia is no longer subject to U.S. federal income tax examinations by tax authorities for years prior to 2012. Additionally, with few exceptions, Columbia is no longer subject to U.S. state tax examinations for years prior to 2009.

Recent_Accounting_Pronouncemen

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]	'
Recent Accounting Pronouncements	'
	(15) Recent Accounting Pronouncements
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers: Topic 606” (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.
	ASU 2014-09 is effective for us in our first quarter of fiscal 2017 using either of two methods: (i) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or (ii) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09. We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements.

Interim_Consolidated_Financial1

Interim Consolidated Financial Statements (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Changes and Error Corrections [Abstract]	'
Reclassifications	'
	Reclassifications
	For comparability purposes, certain prior period amounts in the consolidated financial statements have been reclassified to conform to the current period’s presentation within the consolidated statements of operations.
Management Estimates	'
	Management Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures at the date of the financial statements during the reporting period. Significant estimates are used for, but are not limited to revenue recognition, sales return reserves, allowance for doubtful accounts, inventory reserve, impairment analysis of goodwill and intangibles including their useful lives, deferred tax assets, liabilities and valuation allowances, common stock warrant valuations, and fair value of stock options. On an ongoing basis, management evaluates its estimates. Actual results could differ from those estimates.
Sales Returns Reserves	'
	Currently there is no sales returns reserve as the return rights obligation has elapsed for all products for which Columbia provided a right of return. Products sold to Merck Serono and Actavis are not returnable to Columbia nor is Columbia responsible for returns to Merck Serono on international product sales. A sales return reserve previously existed for Columbia’s historic return policy which allowed product to be returned for a period beginning three months prior to the product expiration date and ending twelve months after the product expiration date. Columbia was only responsible for sales returns for CRINONE and PROCHIEVE products sold to domestic customers prior to the Actavis transaction in July 2010, and for STRIANT sold prior to the sale of STRIANT® (testosterone buccal system) to Auxilium Pharmaceuticals LLC (“Auxilium”) in April 2011.
Recent Accounting Pronouncements	'
	In May 2014, the FASB issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers: Topic 606” (ASU 2014-09), to supersede nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.
	ASU 2014-09 is effective for us in our first quarter of fiscal 2017 using either of two methods: (i) retrospective to each prior reporting period presented with the option to elect certain practical expedients as defined within ASU 2014-09; or (ii) retrospective with the cumulative effect of initially applying ASU 2014-09 recognized at the date of initial application and providing certain additional disclosures as defined per ASU 2014-09. We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements.

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory	'
	overhead. Inventories consist of the following (in thousands):
		September 30,		December 31,
		2014		2013
	Raw materials	$	480	$	771
	Work in process		1,677		775
	Finished goods		700		1,038
	Total	$	2,857	$	2,584

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Changes to Goodwill	'
	Changes to goodwill during the nine months ended September 30, 2014 were as follows (in thousands):
		Total
	Balance—December 31, 2013	$	11,152
	Effects of foreign currency translation		(170	)
	Balance—September 30, 2014	$	10,982
Changes to Intangible Assets	'
	Intangible assets consist of the following at September 30, 2014 and December 31, 2013 (in thousands):
		Trademark			Developed			Customer			Total
					Technology			Relationships
	Gross carrying amount—September 30, 2014	$	300		$	1,370		$	1,240		$	2,910
	Translation adjustment		9			41			37			87
	Accumulated amortization		(107	)		(282	)		(190	)		(579	)
	Balance—September 30, 2014	$	202		$	1,129		$	1,087		$	2,418
		Trademark			Developed			Customer			Total
					Technology			Relationships
	Gross carrying amount—December 31, 2013	$	300		$	1,370		$	1,240		$	2,910
	Translation adjustment		13			62			56			131
	Accumulated amortization		(36	)		(91	)		(86	)		(213	)
	Balance—December 31, 2013	$	277		$	1,341		$	1,210		$	2,828
Amortization Expense on Existing Intangible Assets for Next Five Years and Beyond	'
	As of September 30, 2014, amortization expense on existing intangible assets for the next five years and beyond is as follows (in thousands):
	Year ending December 31,	Total
	Remainder of 2014	$	137
	2015		527
	2016		478
	2017		380
	2018		348
	2019 and thereafter		548
	Total	$	2,418

Debt_and_other_Contractual_Obl1

Debt and other Contractual Obligations (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Summary of Other Income on Obligation	'
	The amount of other income on the obligation that will be recognized provided the Company remains in compliance with the covenants will be the following (in thousands):
	Year	Total
	Remainder of 2014	$	130
	2015		585
	2016		844
	2017		779
	Total	$	2,338

Geographic_Information_and_Con1

Geographic Information and Concentrations (Tables)	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Selected Information by Geographic Area	'
	The following tables show selected information by geographic area (in thousands):
	Revenues:
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	United States	$	4,428	$	1,026	$	9,074	$	2,928
	Switzerland		6,039		5,456		13,112		17,822
	Other countries		996		644		3,382		669
	Total	$	11,463	$	7,126	$	25,568	$	21,419
	Total assets:
		September 30,		December 31,
		2014		2013
	United States	$	17,251	$	20,278
	Switzerland		757		3,063
	United Kingdom		35,529		36,487
	Other countries		185		264
	Total	$	53,722	$	60,092
	Long-lived assets:
		September 30,		December 31,
		2014		2013
	United States	$	254	$	306
	Switzerland		7		22
	United Kingdom		13,308		12,987
	Other countries		2		—
	Total	$	13,571	$	13,315

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Schedule of Property and Equipment	'
	Property and equipment consists of the following (in thousands):
		Estimated	September 30, 2014			December 31, 2013
		Useful Life	Cost			Cost
		(Years)
	Machinery and equipment	10-Mar	$	5,212		$	4,288
	Furniture and fixtures	5-Mar		1,019			1,010
	Computer equipment and software	3		186			183
	Buildings and leasehold improvements	Up to 39		9,469			9,616
	Land	Indefinite		617			627
	Construction in-process			642			104
				17,145			15,828
	Less: Accumulated depreciation			(3,663	)		(2,602	)
	Total		$	13,482		$	13,226

Sales_Returns_Reserves_Tables

Sales Returns Reserves (Tables)	9 Months Ended
	Sep. 30, 2014
Text Block [Abstract]	'
Analysis of Reserve for Sales	'
	An analysis of the reserve for sales returns at September 30, 2014 is as follows (in thousands):
		Total
	Balance—December 31, 2013	$	138
	Provision:
	Related to current period sales		—
	Related to prior period sales		(136	)
			2
	Returns:
	Related to current period sales		—
	Related to prior period sales		(2	)
			(2	)
	Balance—September 30, 2014	$	—

Net_Income_Per_Common_Share_Ta

Net Income Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Calculation of Basic and Diluted Income Per Common and Common Equivalent Share	'
	The calculation of basic and diluted income per common and common equivalent share is as follows (in thousands except for per share data):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Basic income per common share
	Net income	$	3,670		$	1,718		$	4,292		$	5,617
	Less: Preferred stock dividends		(7	)		(7	)		(21	)		(21	)
	Net income applicable to common stock	$	3,663		$	1,711		$	4,271		$	5,596
	Basic weighted average number of common shares outstanding		10,749			11,138			11,339			10,994
	Basic net income per common share	$	0.34		$	0.15		$	0.38		$	0.51
	Diluted income per common share
	Net income applicable to common stock	$	3,663		$	1,711		$	4,271		$	5,596
	Add: Preferred stock dividends		7			7			21			21
	Less: Fair value of stock warrants for dilutive warrants		(1	)		(428	)		(380	)		(478	)
	Net income applicable to dilutive common stock	$	3,669		$	1,290		$	3,912		$	5,139
	Basic weighted average number of common shares outstanding		10,749			11,138			11,339			10,994
	Effect of dilutive securities
	Dilutive stock awards		—			13			—			12
	Dilutive preferred share conversions		9			142			16			142
			9			155			16			154
	Diluted weighted average number of common shares outstanding		10,758			11,293			11,355			11,148
	Diluted net income per common share	$	0.34		$	0.11		$	0.34		$	0.46

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Schedule of Accumulated Other Comprehensive Income	'
	Changes to accumulated other comprehensive income during the nine months ended September 30, 2014 were as follows (in thousands):
		Translation			Accumulated Other
		Adjustment			Comprehensive
					Income
	Balance—December 31, 2013	$	1,370		$	1,370
	Current period other comprehensive income		(374	)		(374	)
	Balance—September 30, 2014	$	996		$	996

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Stock-Based Compensation Expense Allocation	'
	Total stock-based compensation expense was recorded to cost of revenues and operating expenses based upon the functional responsibilities of the individuals holding the respective options as follows (in thousands):
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014			2013		2014		2013
	Cost of revenues	$	15		$	5	$	28	$	10
	Sales and marketing		13			—		29		—
	General and administrative		83			60		400		328
	Total	$	111		$	65	$	457	$	338
Assumptions Used to Weighted-Average Grant Date Fair Values of Options Granted	'
	The weighted-average grant date fair values of the options granted during the nine months ended September 30, 2014 and 2013 were $4.51 and $3.52, respectively, using the following assumptions:
		Nine Months Ended
		September 30,
		2014			2013
	Risk free interest rate		1.64	%	0.71%-0.76%
	Expected term		4.75 years		4.75 years
	Dividend yield		—		—
	Expected volatility		81.36	%	96.52%-97.02%

Related_Party_Transactions_Tab

Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions	'
	The table below presents the transactions between the Company and Actavis during the three months ended September 30, 2014 and 2013 and the nine months ended September 30, 2014 (prior to the time Actavis ceased to be a related party) and the nine months ended September 30, 2013 (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	Revenues
	Product revenues	$	—	$	—	$	167	$	—
	Royalties		—		888		714		2,524
	Total revenues	$	—	$	888	$	881	$	2,524

Inventories_Schedule_of_Invent

Inventories - Schedule of Inventory (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory, Net, Items Net of Reserve Alternative [Abstract]	'	'
Raw materials	$480	$771
Work in process	1,677	775
Finished goods	700	1,038
Total	$2,857	$2,584

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets - Schedule of Changes to Goodwill (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Beginning balance	$11,152
Effects of foreign currency translation	-170
Ending balance	$10,982

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets - Changes to Intangible Assets (Detail) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	$2,910	$2,910
Translation adjustment	87	131
Accumulated amortization	-579	-213
Balance	2,418	2,828
Trademark [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	300	300
Translation adjustment	9	13
Accumulated amortization	-107	-36
Balance	202	277
Developed Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	1,370	1,370
Translation adjustment	41	62
Accumulated amortization	-282	-91
Balance	1,129	1,341
Customer Relationships [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	1,240	1,240
Translation adjustment	37	56
Accumulated amortization	-190	-86
Balance	$1,087	$1,210

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Intangible Liability Disclosure [Abstract]	'	'	'	'
Amortization expense	$0.10	$0	$0.40	$0

Goodwill_and_Intangible_Assets5

Goodwill and Intangible Assets - Amortization Expense on Existing Intangible Assets for Next Five Years and Beyond (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]	'	'
Remainder of 2014	$137	'
2015	527	'
2016	478	'
2017	380	'
2018	348	'
2019 and thereafter	548	'
Total	$2,418	$2,828

Recovered_Sheet1

Debt and Other Contractual Obligations - Additional Information (Detail) (Molecular Profiles [Member], USD $)	1 Months Ended	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2014
			Facilities
Debt Instrument [Line Items]	'	'	'
Debt assumed	$3.90	'	'
Number of loan facilities	'	'	3
Withdrawn amount	'	'	3.9
Owes due to foreign currency revaluation	'	3.8	3.8
Weighted average interest rate for the period	'	3.00%	3.00%
Loan facilities repayment period	'	'	'15 years
Business acquisition maturity period	'	'	'2017-10
Loan Facility One [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Loan repayment commencement period	'	'	'2013-02
Interest rate at the end of period	'	2.45%	2.45%
Loan facilities bear interest rate	'	'	1.95%
Loan facility interest rate description	'	'	'Base rate plus 1.95%
Loan Facility Two [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Loan repayment commencement period	'	'	'2013-10
Interest rate at the end of period	'	3.05%	3.05%
Loan facilities bear interest rate	'	'	2.55%
Loan facility interest rate description	'	'	'Base rate plus 2.55%
Loan Facility Three [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Loan repayment commencement period	'	'	'2013-10
Loan facilities bear interest rate	'	3.52%	3.52%
Regional Growth Fund [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Debt assumed	'	'	2.5
Deferred revenue	'	$2.30	$2.30

Recovered_Sheet2

Debt and Other Contractual Obligations - Summary of Other Income on Obligation (Detail) (Regional Growth Fund [Member], Molecular Profiles [Member], USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Regional Growth Fund [Member] | Molecular Profiles [Member]	'
Contractual Obligation [Line Items]	'
Remainder of 2014	$130
2015	585
2016	844
2017	779
Total	$2,338

Geographic_Information_and_Con2

Geographic Information and Concentrations - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Number of operating segments	'	'	1	'
Number of operational location	1	'	1	'
Sales Revenue, Net [Member] | Merck Serono [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Net revenues	52.00%	77.00%	49.00%	83.00%
Sales Revenue, Net [Member] | Actavis [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Net revenues	9.00%	12.00%	13.00%	12.00%
Lil' Drug Store Products, Inc. [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Net revenues	19.00%	2.00%	'	'

Geographic_Information_and_Con3

Geographic Information and Concentrations - Selected Information by Geographic Area (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'
Total revenues	$11,463	$7,126	$25,568	$21,419	'
Total assets	53,722	'	53,722	'	60,092
Total Long-lived Assets	13,571	'	13,571	'	13,315
United States [Member]	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'
Total revenues	4,428	1,026	9,074	2,928	'
Total assets	17,251	'	17,251	'	20,278
Total Long-lived Assets	254	'	254	'	306
Switzerland [Member]	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'
Total revenues	6,039	5,456	13,112	17,822	'
Total assets	757	'	757	'	3,063
Total Long-lived Assets	7	'	7	'	22
Other Countries [Member]	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'
Total revenues	996	644	3,382	669	'
Total assets	185	'	185	'	264
Total Long-lived Assets	2	'	2	'	'
United Kingdom [Member]	'	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'	'
Total assets	35,529	'	35,529	'	36,487
Total Long-lived Assets	$13,308	'	$13,308	'	$12,987

Property_and_Equipment_Schedul

Property and Equipment - Schedule of Property and Equipment (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, gross	$17,145	$15,828
Less: Accumulated depreciation	-3,663	-2,602
Total	13,482	13,226
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, gross	5,212	4,288
Machinery and Equipment [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment useful life (in years)	'3 years	'
Machinery and Equipment [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment useful life (in years)	'10 years	'
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, gross	1,019	1,010
Furniture and Fixtures [Member] | Minimum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment useful life (in years)	'3 years	'
Furniture and Fixtures [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment useful life (in years)	'5 years	'
Computer Equipment and Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment useful life (in years)	'3 years	'
Property plant and equipment, gross	186	183
Buildings and Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, gross	9,469	9,616
Buildings and Leasehold Improvements [Member] | Maximum [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment useful life (in years)	'39 years	'
Land [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, plant and equipment useful life (in years)	'Indefinite	'
Property plant and equipment, gross	617	627
Construction in-Process [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property plant and equipment, gross	$642	$104

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Depreciation [Abstract]	'	'	'	'
Depreciation expense	$0.40	$0.20	$1.10	$0.40

Sales_Returns_Reserves_Additio

Sales Returns Reserves - Additional Information (Detail) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]	'
Period of product return prior to expiration	'3 months
Period of product return after expiration	'12 months
Allowance for Sales Returns [Member]	'
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]	'
Sales returns reserve	2
Current Period Sales [Member] | Allowance for Sales Returns [Member]	'
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]	'
Sales returns reserve	0

Sales_Returns_Reserves_Analysi

Sales Returns Reserves - Analysis of Reserve for Sales (Detail) (Allowance for Sales Returns [Member], USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]	'
Balance at beginning of year	$138
Provision:	'
Sales allowances	2
Returns:	'
Sales returns	-2
Balance at end of period	0
Current Period Sales [Member]	'
Provision:	'
Sales allowances	0
Returns:	'
Sales returns	0
Prior Period Sales [Member]	'
Provision:	'
Sales allowances	-136
Returns:	'
Sales returns	($2)

Net_Income_Per_Common_Share_Ca

Net Income Per Common Share - Calculation of Basic and Diluted Income Per Common and Common Equivalent Share (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Basic income per common share	'	'	'	'
Net income	$3,670	$1,718	$4,292	$5,617
Less: Preferred stock dividends	-7	-7	-21	-21
Net income applicable to common stock	3,663	1,711	4,271	5,596
Basic weighted average number of common shares outstanding	10,749	11,138	11,339	10,994
Basic net income per common share	$0.34	$0.15	$0.38	$0.51
Diluted income per common share	'	'	'	'
Net income applicable to common stock	3,663	1,711	4,271	5,596
Add: Preferred stock dividends	7	7	21	21
Less: Fair value of stock warrants for dilutive warrants	-1	-428	-380	-478
Net income applicable to dilutive common stock	$3,669	$1,290	$3,912	$5,139
Basic weighted average number of common shares outstanding	10,749	11,138	11,339	10,994
Effect of dilutive securities	'	'	'	'
Dilutive stock awards	'	13	'	12
Dilutive preferred share conversions	9	142	16	142
Weighted average number of diluted shares outstanding adjustment	9	155	16	154
Diluted weighted average number of common shares outstanding	10,758	11,293	11,355	11,148
Diluted net income per common share	$0.34	$0.11	$0.34	$0.46

Net_Income_Per_Common_Share_Ad

Net Income Per Common Share - Additional Information (Detail)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share	1.8	1.6	1.8	1.6

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income - Schedule of Accumulated Other Comprehensive Income (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Translation Adjustment, Balance-December 31, 2013	'	'	$1,370	'
Translation Adjustment, Current period other comprehensive income	-1,191	638	-374	635
Translation Adjustment, Balance-September 30, 2014	996	'	996	'
Accumulated Other Comprehensive Income, Balance-December 31, 2013	'	'	1,370	'
Accumulated Other Comprehensive Income, Current period other comprehensive income	-1,191	638	-374	538
Accumulated Other Comprehensive Income, Balance-September 30, 2014	$996	'	$996	'

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'	'
Share based compensation	$100,000	$100,000	$457,000	$338,000
Cash received from option exercised	'	'	17,000	10,000
Company options granted to employees, in shares	'	'	222,000	88,750
Weighted-average grand date fair values of options granted	'	'	$4.51	$3.52
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized	$1,100,000	'	$1,100,000	'
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition	'	'	'2 years 11 months 9 days	'

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Allocation (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total	$111	$65	$457	$338
Cost of Revenues [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total	15	5	28	10
Sales and Marketing [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total	13	'	29	'
General and Administrative [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total	$83	$60	$400	$328

StockBased_Compensation_Assump

Stock-Based Compensation - Assumptions Used to Weighted-Average Grant Date Fair Values of Options Granted (Detail)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]	'	'
Risk free interest rate	1.64%	'
Expected term	'4 years 9 months	'4 years 9 months
Dividend yield	'	'
Expected volatility	81.36%	'
Minimum [Member]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]	'	'
Risk free interest rate	'	0.71%
Expected volatility	'	96.52%
Maximum [Member]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used [Line Items]	'	'
Risk free interest rate	'	0.76%
Expected volatility	'	97.02%

Legal_Proceedings_Additional_I

Legal Proceedings - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2014	Feb. 06, 2012
	Defendant	Complaints
Commitments and Contingencies Disclosure [Abstract]	'	'
Number of putative securities class action complaints (in complaints)	'	2
Number of officers added as defendants	3	'
Number of days to plead cognizable action	'30 days	'

Fair_Value_of_Financial_Instru1

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Oct. 31, 2009	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Debt Instrument Fair Value Carrying Value [Abstract]	'	'	'	'	'	'
Common stock, shares authorized under plan, in shares	1,362,500	12,183,000	'	12,183,000	'	12,152,000
Warrants to purchase common stock, in shares	681,275	'	'	'	'	'
Derivative liability, fair value, gross liability	'	$0	'	$0	'	$379
Derivative gain/income fair value of stock warrants	'	$1	$428	$380	$478	'

Related_Party_Transactions_Add

Related Party Transactions - Additional Information (Detail) (USD $)	9 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014	Mar. 07, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]	'	'	'
Amounts due from related parties	'	'	$900,000
Actavis [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Percentage of ownership of outstanding common stock	'	11.50%	'
Number of shares repurchased	1.4	'	'
Number of shares repurchased price per share	$6.08	'	'
Percentage of closing price discount on share repurchase	10.75%	'	'
Purchase price	8,500,000	'	'
Amounts due from related parties	'	'	900,000
Amounts due to related parties	0	'	0
Actavis [Member] | CRINONE Royalties [Member]	'	'	'
Related Party Transaction [Line Items]	'	'	'
Percentage of royalties received	10.00%	'	'
Annual net sales	15.00%	'	'
Percentage of royalties received for sales between range	20.00%	'	'
Condition one for royalties received	150,000,000	'	'
Condition two for royalties received	250,000,000	'	'
Purchase of remaining raw materials	$200,000	'	'

Related_Party_Transactions_Sch

Related Party Transactions - Schedule of Related Party Transactions (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Related Party Transaction [Line Items]	'	'	'	'
Product revenues	'	'	$167	'
Royalties	'	888	714	2,524
Actavis [Member]	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Product revenues	'	'	167	'
Royalties	'	888	714	2,524
Total revenues	'	$888	$881	$2,524

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Income tax expense	($110)	$3	$68	$8
Effective tax rate	-3.00%	0.20%	2.00%	0.10%